Even when the results are unblinded, NWBO is not going to be free at all to shout until they get approved by the FDA. That's a very basic fact of biotech that many inexperienced investors fail to understand and then they get frustrated and angry about. But that is a large reason why these stocks are extremely binary and this really is Biotech investing 101.
Agreed. I think the company understands this and that’s why Dave Innes was hired for this purpose and not just to replace LG . I see a coordinated effort with a PR firm to tell the story better once results are out. He is likely working to lay the groundwork in the meantime. We got pretty good coverage outside of the US with the JTM publication so much work to do within the country. UCLA has the credibility and credentials to lead the PR fight and if we get endorsements from the combo partners, so much the better.
Thanks for your incisive analyses. Always enjoyed reading your posts.
News 
Market Data 
Discover 
